Overview
Hepatobiliary and pancreatic imaging
Liver cancer (hepatocellular carcinoma)
Fatty liver, NAFLD, and NASH
Chronic liver disease and cirrhosis
Pancreatic cancer
Technical development in MRI
Quantitative imaging
Liver cancer (hepatocellular carcinoma)
Fatty liver, NAFLD, and NASH
Chronic liver disease and cirrhosis
Pancreatic cancer
Technical development in MRI
Quantitative imaging
Current Appointments & Affiliations
Professor of Radiology
·
2022 - Present
Radiology, Abdominal Imaging,
Radiology
Professor in Medicine
·
2022 - Present
Medicine, Gastroenterology,
Medicine
Member of the Duke Cancer Institute
·
2016 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Predictors of hepatocellular carcinoma in LR-M category lesions, a multi-institutional analysis.
Journal Article Abdom Radiol (NY) · November 2025 PURPOSE: The Liver Imaging Reporting and Data System (LI-RADS, LR) provides a framework for diagnosing hepatocellular carcinoma (HCC, LR-5). However, not all HCCs meet LR-5 criteria and are instead categorized as LR-M, probably or definitely malignant but ... Full text Link to item CiteACR Appropriateness Criteria® Screening, Locoregional Assessment, and Surveillance of Pancreatic Ductal Adenocarcinoma: 2025 Update.
Journal Article J Am Coll Radiol · November 2025 Pancreatic ductal adenocarcinoma is a highly lethal cancer that often presents with vague and indolent symptoms leading to advanced stage diagnosis. Imaging plays a crucial role in the diagnosis, assessment of locoregional and metastatic disease, surgical ... Full text Link to item CiteACR Appropriateness Criteria® Staging and Follow-Up of Primary Liver Cancer.
Journal Article J Am Coll Radiol · November 2025 Liver cancer is the sixth most common cancer worldwide, with 905,677 new cases in 2020, and the third leading cause of cancer-related deaths globally. Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer and accounts for approxima ... Full text Link to item CiteRecent Grants
Evaluation of Efficacy, Safety and Tolerability of NGM282-PS-231 - NGM08
Clinical TrialPrincipal Investigator · Awarded by NGM Biopharmaceuticals, Inc. · 2024 - 2031Wake Research WAKE03 - BI 1404-0044 A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with non-cirrhotic non-alcoholic steatohe
Clinical TrialPrincipal Investigator · Awarded by M3 Wake Research Inc · 2025 - 2028BI 1404-0064 A Phase III double-blind, randomized, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatit
Clinical TrialPrincipal Investigator · Awarded by M3 Wake Research Inc · 2025 - 2028View All Grants
Education, Training & Certifications
University of Iowa ·
2004
M.D.